These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
346 related articles for article (PubMed ID: 10343002)
21. United States Food and Drug Administration requirements for approval of generic drug products. Meyer MC J Clin Psychiatry; 2001; 62 Suppl 5():4-9; discussion 23-4. PubMed ID: 11305846 [TBL] [Abstract][Full Text] [Related]
24. The effectiveness of generic agents in psychopharmacologic treatment. Kumet R; Gelenberg AJ Essent Psychopharmacol; 2005; 6(2):104-11. PubMed ID: 15765794 [TBL] [Abstract][Full Text] [Related]
25. Comparison of the bioequivalence of generic versus branded clozapine. Ereshefsky L; Glazer WM J Clin Psychiatry; 2001; 62 Suppl 5():25-7. PubMed ID: 11305845 [No Abstract] [Full Text] [Related]
26. The Hatch-Waxman Act: balancing competing interests or survival of the fittest? Behrendt KE Food Drug Law J; 2002; 57(2):247-71. PubMed ID: 12436990 [No Abstract] [Full Text] [Related]
27. Look-alike drugs and unfair competition. An update of Inwood Laboratories v. Ives Laboratories. Shapiro LJ Am Pharm; 1985 Oct; NS25(10):49-50. PubMed ID: 4061279 [No Abstract] [Full Text] [Related]
28. Generic and alternative brand-name pharmaceutical equivalents: select with caution. Hendeles L; Hochhaus G; Kazerounian S Am J Hosp Pharm; 1993 Feb; 50(2):323-9. PubMed ID: 8480793 [No Abstract] [Full Text] [Related]
29. Wellbutrin versus generic bupropion. Med Lett Drugs Ther; 2008 Jul; 50(1290):54-5. PubMed ID: 18617874 [No Abstract] [Full Text] [Related]
31. Generic substitution: issues for problematic drugs. Henderson JD; Esham RH South Med J; 2001 Jan; 94(1):16-21. PubMed ID: 11213935 [TBL] [Abstract][Full Text] [Related]
32. Comment: Pharmacy and generic substitution of antiepileptic drugs: missing in action? Hatton RC Ann Pharmacother; 2007 Sep; 41(9):1550-1; author reply 1551-2. PubMed ID: 17652128 [No Abstract] [Full Text] [Related]
33. Pharmacist compounding of analgesic medication: the risk of a little-known practice. Johnson P; Jones G J Fla Med Assoc; 1997 Jan; 84(1):13-5. PubMed ID: 9037992 [No Abstract] [Full Text] [Related]
34. Repercussions of the Drug Price Competition and Patent Term Restoration Act of 1984. Hogan GF Am J Hosp Pharm; 1985 Apr; 42(4):849-51. PubMed ID: 4014238 [TBL] [Abstract][Full Text] [Related]
35. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering. Paine CS Seton Hall Law Rev; 2003; 33(2):479-510. PubMed ID: 12715807 [No Abstract] [Full Text] [Related]
36. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300 [TBL] [Abstract][Full Text] [Related]
37. [Pharmaceuticals: the banning of "tested" generic drugs from India; the first 3D tablet]. Nau JY Rev Med Suisse; 2015 Aug; 11(482):1506-7. PubMed ID: 26449106 [No Abstract] [Full Text] [Related]
39. Market exclusivity after a prescription to nonprescription drug switch: striking the right balance between innovation and competition. Kraushaar KJ Food Drug Law J; 1999; 54(2):243-4. PubMed ID: 11758581 [No Abstract] [Full Text] [Related]